Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Fate Therapeutics Inc (FATE)  
$3.70 0.18 (4.64%) as of 4:30 Wed 5/8


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 118,506,000
Market Cap: 438.47(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.65 - $8.35
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 7.7
Insider 3/6 Months : 8.3
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 44,630 44,630 471,648
Total Buy Value $0 $166,024 $166,024 $2,724,191
Total People Bought 0 1 1 2
Total Buy Transactions 0 1 1 6
Total Shares Sold 2,447 78,990 96,836 590,364
Total Sell Value $19,013 $301,730 $380,390 $5,527,958
Total People Sold 1 4 6 14
Total Sell Transactions 1 9 14 36
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 297
  Page 4 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mendlein John Director   –       •      –    2022-03-10 4 OE $1.63 $51,446 D/D 31,562 191,017     -
   Chu Yu-Waye Chief Medical Officer   •       –      –    2022-01-25 4 A $0.00 $0 D/D 33,302 155,095     -
   Valamehr Bahram See Remarks   •       –      –    2022-01-25 4 A $0.00 $0 D/D 33,302 179,834     -
   Dulac Edward J Iii Chief Financial Officer   •       –      –    2022-01-25 4 A $0.00 $0 D/D 33,302 141,936     -
   Tahl Cindy See Remarks   •       –      –    2022-01-25 4 A $0.00 $0 D/D 33,302 189,151     -
   Plavsic Mark Chief Technical Officer   •       –      –    2022-01-25 4 A $0.00 $0 D/D 33,302 130,842     -
   Wolchko J Scott President and CEO   •       •      –    2022-01-21 4 AS $38.02 $380,200 D/D (10,000) 431,546 -39%     
   Wolchko J Scott President and CEO   •       •      –    2022-01-21 4 OE $2.70 $27,000 D/D 10,000 441,546     -
   Wolchko J Scott President and CEO   •       •      –    2022-01-20 4 AS $40.21 $1,206,300 D/D (30,000) 431,546 -40%     
   Wolchko J Scott President and CEO   •       •      –    2022-01-20 4 OE $2.73 $81,900 D/D 30,000 461,546     -
   Wolchko J Scott President and CEO   •       •      –    2022-01-11 4 S $48.50 $709,027 D/D (14,566) 431,546 51%     
   Dulac Edward J Iii Chief Financial Officer   •       –      –    2022-01-11 4 S $48.25 $85,757 D/D (1,770) 108,634 51%     
   Chu Yu-Waye Senior VP Clinical Development   •       –      –    2022-01-11 4 S $48.44 $192,340 D/D (3,965) 121,793 51%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2022-01-11 4 S $48.46 $262,975 D/D (5,419) 155,849 51%     
   Valamehr Bahram Chief R&D Officer   •       –      –    2022-01-11 4 S $48.44 $221,655 D/D (4,570) 146,532 51%     
   Valamehr Bahram Chief R&D Officer   •       –      –    2022-01-10 4 S $46.33 $259,558 D/D (5,596) 151,102 55%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2022-01-10 4 S $46.37 $359,313 D/D (7,738) 161,268 55%     
   Wolchko J Scott President and CEO   •       •      –    2022-01-10 4 S $46.36 $1,600,534 D/D (34,156) 446,112 55%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2022-01-03 4 AS $57.76 $2,966,853 D/D (50,000) 169,006 -64%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2022-01-03 4 OE $6.55 $327,500 D/D 50,000 219,006     -
   Dulac Edward J Iii Chief Financial Officer   •       –      –    2021-12-20 4 AS $60.00 $958,620 D/D (15,977) 110,404 -53%     
   Dulac Edward J Iii Chief Financial Officer   •       –      –    2021-12-20 4 OE $35.52 $512,802 D/D 14,437 126,381     -
   Valamehr Bahram Chief R&D Officer   •       –      –    2021-12-13 4 AS $45.68 $1,191,406 D/D (25,000) 156,698 -28%     
   Valamehr Bahram Chief R&D Officer   •       –      –    2021-12-13 4 OE $2.73 $68,250 D/D 25,000 181,698     -
   Chu Yu-Waye Senior VP Clinical Development   •       –      –    2021-12-10 4 AS $49.32 $385,948 D/D (7,500) 125,758 -30%     
  297 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us